COST-EFFECTIVENESS OF EPISODIC OR MAINTENANCE INFLIXIMAB VERSUS STANDARD TREATMENT IN AN INCIDENCE COHORT OF CROHN'S DISEASE PATIENTS WITH 10-YEARS FOLLOW-UP

被引：0
|
作者：
Odes, S. [1 ]
Greenberg, D. [2 ]
Vardi, H. [2 ]
Friger, M. [2 ]
Stockbrugger, R. [3 ]
Munkholm, P. [4 ,5 ]
机构：
[1] Soroka Med Ctr, IL-84101 Beer Sheva, Israel
[2] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel
[3] Univ Hosp Maastricht, Maastricht, Netherlands
[4] Univ Copenhagen, Copenhagen, Denmark
[5] Herlev Hosp, Copenhagen, Denmark
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.772
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A329 / A330
页数：2
相关论文
共 50 条
  • [31] Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
    Negoescu, Diana M.
    Enns, Eva A.
    Swanhorst, Brooke
    Baumgartner, Bonnie
    Campbell, James P.
    Osterman, Mark T.
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    Vaughn, Byron P.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (01) : 103 - 111
  • [32] Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy
    Alizadeh, Elmar R.
    Dervieux, Thierry
    Vermeire, Severine
    Dubinsky, Marla
    D'Haens, Geert
    Laharie, David
    Shim, Andrew
    Vaughn, Byron P.
    PHARMACOTHERAPY, 2024, 44 (04): : 331 - 342
  • [33] Successful treatment of neuro-Behcet's disease with infliximab: four years follow-up
    Kaur, Manjinder
    Nia, Emily S.
    Millius, Rebecca A.
    Sudano, Dominick G.
    Lisse, Jeffrey R.
    RHEUMATOLOGY REPORTS, 2015, 7 (01) : 14 - 16
  • [34] Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults
    Lindsay, J.
    Punekar, Y. S.
    Morris, J.
    Chung-Faye, G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (01) : 76 - 87
  • [35] Cost-Effectiveness Comparative Study for Clinical, Surgical or Percutaneous Treatment in Patients With Stable Multivessel Coronary Artery Disease: 10 Year Follow-Up
    Magalhaes, Cibelle D.
    Hueb, Whady
    Scudeler, Thiago
    Favarato, Desiderio
    Lima, Eduardo
    Vieira, Ricardo D.
    Bocchi, Edimar
    CIRCULATION, 2017, 136
  • [36] Evaluation of Treatment Patterns Among Crohn's Disease Patients Initiating Biologics With Three Years of Follow-Up
    Zhao, Ruizhi
    Ding, Zhijie
    Gupta, Parul
    Gozalo, Laurence
    Bruette, Robert
    Johnson, Victor
    Maughn, Keshia
    Kachroo, Sumesh
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S596 - S597
  • [37] IMPACT OF NON-INVASIVE VENTILATORY SUPPORT IN AN OBSTRUCTIVE SLEEP APNEA COHORT OF PATIENTS: A 10-YEARS FOLLOW-UP STUDY ON CARDIOVASCULAR EVENTS INCIDENCE
    Alves Moreira, A. C.
    Martins, N.
    Drummond, M.
    SLEEP MEDICINE, 2019, 64 : S13 - S14
  • [38] Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
    Aliyev, Elmar R.
    Hay, Joel W.
    Hwang, Caroline
    PHARMACOTHERAPY, 2019, 39 (02): : 118 - 128
  • [39] THE COST-EFFECTIVENESS OF HELICOBACTER-PYLORI ERADICATION VERSUS MAINTENANCE AND EPISODIC TREATMENT IN DUODENAL-ULCER PATIENTS IN SWEDEN
    UNGE, P
    JONSSON, B
    STALHAMMAR, NO
    PHARMACOECONOMICS, 1995, 8 (05) : 410 - 427
  • [40] Safety of Infliximab and Other Crohn's Disease Therapies: Treat™ Registry Data With a Mean of 5 Years of Follow-up
    Lichtenstein, Gary R.
    Cohen, Russell D.
    Feagan, Brian G.
    Salzberg, B. A.
    Turner, Michelle
    Mink, David
    Langholff, Wayne K.
    Diamond, Robert
    Sandborn, William J.
    GASTROENTEROLOGY, 2011, 140 (05) : S773 - S773
12345